O	0	1	3	3	CD	B-NP
O	1	2	.	.	.	I-NP
O	2	3	1	1	CD	I-NP
O	3	4	.	.	.	O

O	5	12	Glucose	Glucose	NN	B-NP
O	13	22	Tolerance	Tolerance	NN	I-NP
O	23	27	Test	Test	NN	I-NP
O	28	30	at	at	IN	B-PP
O	31	38	Various	Various	NNP	B-NP
O	39	44	Times	Times	NNP	I-NP
O	45	54	following	follow	VBG	B-PP
O	55	61	Dosing	Dosing	NNP	B-NP

O	62	65	DIO	DIO	NN	B-NP
O	66	70	mice	mouse	NNS	I-NP
O	71	75	were	be	VBD	B-VP
O	76	83	treated	treat	VBN	I-VP
O	84	88	with	with	IN	B-PP
O	89	90	a	a	DT	B-NP
O	91	97	single	single	JJ	I-NP
O	98	100	IV	IV	CD	I-NP
O	101	105	dose	dose	NN	I-NP
O	106	108	of	of	IN	B-PP
O	109	113	CNTO	CNTO	NN	B-NP
O	114	117	530	530	CD	I-NP
O	118	119	(	(	(	O
O	119	120	0	0	CD	B-NP
O	120	121	.	.	.	O
O	121	122	3	3	CD	B-NP
O	123	125	mg	mg	NN	I-NP
O	125	126	/	/	SYM	B-NP
O	126	128	kg	kg	NN	I-NP
O	128	129	)	)	)	O
O	129	130	,	,	,	O
O	131	134	and	and	CC	O
O	135	142	glucose	glucose	NN	B-NP
O	143	153	metabolism	metabolism	NN	I-NP
O	154	157	was	be	VBD	B-VP
O	158	167	monitored	monitor	VBN	I-VP
O	168	173	using	use	VBG	I-VP
O	174	176	an	an	DT	B-NP
B-Immaterial_anatomical_entity	177	192	intraperitoneal	intraperitoneal	JJ	I-NP
O	193	200	glucose	glucose	NN	I-NP
O	201	210	tolerance	tolerance	NN	I-NP
O	211	215	test	test	NN	I-NP
O	216	217	(	(	(	O
O	217	222	IPGTT	IPGTT	NN	B-NP
O	222	223	)	)	)	O
O	224	226	at	at	IN	B-PP
O	227	234	various	various	JJ	B-NP
O	235	240	times	time	NNS	I-NP
O	241	250	following	follow	VBG	B-PP
O	251	257	dosing	dosing	NN	B-NP
O	258	259	(	(	(	O
O	259	262	day	day	NN	B-NP
O	263	264	1	1	CD	I-NP
O	265	267	to	to	TO	B-PP
O	268	270	35	35	CD	B-NP
O	270	271	)	)	)	O
O	271	272	.	.	.	O

O	273	277	CNTO	CNTO	NN	B-NP
O	278	281	530	530	CD	I-NP
O	282	285	did	do	VBD	B-VP
O	286	289	not	not	RB	I-VP
O	290	299	influence	influence	VB	I-VP
O	300	307	glucose	glucose	NN	B-NP
O	308	317	tolerance	tolerance	NN	I-NP
O	318	320	24	24	CD	B-NP
O	321	326	hours	hour	NNS	I-NP
O	327	332	after	after	IN	B-PP
O	333	339	dosing	dosing	NN	B-NP
O	339	340	.	.	.	O

O	341	348	However	However	RB	B-ADVP
O	348	349	,	,	,	O
O	350	351	a	a	DT	B-NP
O	352	363	significant	significant	JJ	I-NP
O	364	375	improvement	improvement	NN	I-NP
O	376	379	was	be	VBD	B-VP
O	380	388	observed	observe	VBN	I-VP
O	389	391	in	in	IN	B-PP
O	392	396	both	both	CC	O
O	397	404	fasting	fast	VBG	B-VP
O	405	412	glucose	glucose	NN	B-NP
O	413	414	(	(	(	O
O	414	417	179	179	CD	B-NP
O	418	419	+	+	SYM	O
O	419	420	/	/	SYM	O
O	420	421	-	-	SYM	O
O	422	424	29	29	CD	B-NP
O	425	431	versus	versus	IN	B-PP
O	432	435	133	133	CD	B-NP
O	436	437	+	+	SYM	O
O	437	438	/	/	SYM	O
O	438	439	-	-	SYM	O
O	440	442	19	19	CD	B-NP
O	443	445	mg	mg	NN	I-NP
O	445	446	/	/	SYM	B-NP
O	446	448	dL	dL	NN	I-NP
O	449	452	for	for	IN	B-PP
O	453	462	untreated	untreated	JJ	B-ADJP
O	463	469	versus	versus	CC	I-ADJP
O	470	477	treated	treat	VBN	I-ADJP
O	477	478	)	)	)	O
O	479	482	and	and	CC	O
O	483	490	overall	overall	JJ	B-NP
O	491	498	glucose	glucose	NN	I-NP
O	499	508	tolerance	tolerance	NN	I-NP
O	509	514	seven	seven	CD	B-NP
O	515	519	days	day	NNS	I-NP
O	520	525	after	after	IN	B-PP
O	526	527	a	a	DT	B-NP
O	528	534	single	single	JJ	I-NP
O	535	539	dose	dose	NN	I-NP
O	540	542	of	of	IN	B-PP
O	543	547	CNTO	CNTO	NN	B-NP
O	548	551	530	530	CD	I-NP
O	552	553	(	(	(	O
O	553	559	Figure	Figure	NN	B-NP
O	560	561	2	2	CD	I-NP
O	561	562	(	(	(	O
O	562	563	b	b	NN	B-NP
O	563	564	)	)	)	O
O	564	565	)	)	)	O
O	565	566	.	.	.	O

O	567	569	In	In	IN	B-PP
O	570	571	a	a	DT	B-NP
O	572	580	separate	separate	JJ	I-NP
O	581	586	study	study	NN	I-NP
O	586	587	,	,	,	O
O	588	591	the	the	DT	B-NP
O	592	600	activity	activity	NN	I-NP
O	601	603	of	of	IN	B-PP
O	604	608	CNTO	CNTO	NN	B-NP
O	609	612	530	530	CD	I-NP
O	613	616	was	be	VBD	B-VP
O	617	625	compared	compare	VBN	I-VP
O	626	628	to	to	TO	B-PP
O	629	630	a	a	DT	B-NP
O	631	638	control	control	NN	I-NP
O	639	646	protein	protein	NN	I-NP
O	647	651	that	that	WDT	B-NP
O	652	658	lacked	lack	VBD	B-VP
O	659	662	the	the	DT	B-NP
O	663	666	EMP	EMP	NN	I-NP
O	666	667	-	-	HYPH	B-NP
O	667	668	1	1	CD	I-NP
O	669	677	peptides	peptide	NNS	I-NP
O	678	680	to	to	TO	B-VP
O	681	687	ensure	ensure	VB	I-VP
O	688	692	that	that	IN	B-SBAR
O	693	696	the	the	DT	B-NP
O	697	705	observed	observe	VBN	I-NP
O	706	713	effects	effect	NNS	I-NP
O	714	718	were	be	VBD	B-VP
O	719	722	due	due	JJ	B-ADJP
O	723	725	to	to	TO	B-PP
O	726	729	the	the	DT	B-NP
O	730	737	peptide	peptide	NN	I-NP
O	738	741	and	and	CC	B-NP
O	742	745	not	not	RB	I-NP
O	746	749	the	the	DT	B-NP
O	750	752	Fc	Fc	NN	I-NP
O	752	753	.	.	.	O

O	754	757	The	The	DT	B-NP
O	758	765	glucose	glucose	NN	I-NP
O	766	774	lowering	lowering	NN	I-NP
O	775	781	effect	effect	NN	I-NP
O	782	785	was	be	VBD	B-VP
O	786	789	not	not	RB	I-VP
O	790	798	observed	observe	VBN	I-VP
O	799	801	in	in	IN	B-PP
O	802	805	the	the	DT	B-NP
O	806	810	mice	mouse	NNS	I-NP
O	811	818	treated	treat	VBN	B-VP
O	819	823	with	with	IN	B-PP
O	824	827	the	the	DT	B-NP
O	828	835	protein	protein	NN	I-NP
O	836	843	lacking	lack	VBG	B-VP
O	844	847	the	the	DT	B-NP
O	848	851	EMP	EMP	NN	I-NP
O	851	852	-	-	HYPH	B-NP
O	852	853	1	1	CD	I-NP
O	854	862	peptides	peptide	NNS	I-NP
O	863	864	(	(	(	O
O	864	868	data	datum	NNS	B-NP
O	869	872	not	not	RB	B-VP
O	873	878	shown	show	VBN	I-VP
O	878	879	)	)	)	O
O	879	880	.	.	.	O

O	881	888	Fasting	Fast	VBG	B-VP
B-Organism_substance	889	894	blood	blood	NN	B-NP
O	895	902	glucose	glucose	NN	I-NP
O	903	911	remained	remain	VBD	B-VP
O	912	920	improved	improve	VBN	I-VP
O	921	923	in	in	IN	B-PP
O	924	927	the	the	DT	B-NP
O	928	935	treated	treat	VBN	I-NP
O	936	943	animals	animal	NNS	I-NP
O	944	946	14	14	CD	B-NP
O	947	950	and	and	CC	I-NP
O	951	953	21	21	CD	I-NP
O	954	958	days	day	NNS	I-NP
O	959	964	after	after	IN	B-PP
O	965	972	CNTO530	CNTO530	NN	B-NP
O	973	982	treatment	treatment	NN	I-NP
O	982	983	,	,	,	O
O	984	987	but	but	CC	O
O	988	991	was	be	VBD	B-VP
O	992	999	similar	similar	JJ	B-ADJP
O	1000	1002	to	to	TO	B-PP
O	1003	1006	the	the	DT	B-NP
O	1007	1016	untreated	untreated	JJ	I-NP
O	1017	1022	group	group	NN	I-NP
O	1023	1028	after	after	IN	B-PP
O	1029	1031	35	35	CD	B-NP
O	1032	1036	days	day	NNS	I-NP
O	1037	1038	(	(	(	O
O	1038	1042	data	datum	NNS	B-NP
O	1043	1046	not	not	RB	B-VP
O	1047	1052	shown	show	VBN	I-VP
O	1052	1053	)	)	)	O
O	1053	1054	.	.	.	O

O	1055	1058	The	The	DT	B-NP
O	1059	1063	area	area	NN	I-NP
O	1064	1069	under	under	IN	B-PP
O	1070	1073	the	the	DT	B-NP
O	1074	1079	curve	curve	NN	I-NP
O	1080	1081	(	(	(	O
O	1081	1084	AUC	AUC	NN	B-NP
O	1084	1085	)	)	)	O
O	1086	1089	for	for	IN	B-PP
O	1090	1093	the	the	DT	B-NP
O	1094	1101	glucose	glucose	NN	I-NP
O	1102	1111	tolerance	tolerance	NN	I-NP
O	1112	1117	tests	test	NNS	I-NP
O	1118	1124	showed	show	VBD	B-VP
O	1125	1126	a	a	DT	B-NP
O	1127	1138	significant	significant	JJ	I-NP
O	1139	1150	improvement	improvement	NN	I-NP
O	1151	1155	with	with	IN	B-PP
O	1156	1160	CNTO	CNTO	NN	B-NP
O	1161	1164	530	530	CD	I-NP
O	1165	1174	treatment	treatment	NN	I-NP
O	1175	1177	on	on	IN	B-PP
O	1178	1182	days	day	NNS	B-NP
O	1183	1184	7	7	CD	I-NP
O	1184	1185	,	,	,	I-NP
O	1186	1188	14	14	CD	I-NP
O	1188	1189	,	,	,	I-NP
O	1190	1192	20	20	CD	I-NP
O	1192	1193	,	,	,	O
O	1194	1197	and	and	CC	O
O	1198	1200	28	28	CD	B-NP
O	1201	1202	(	(	(	O
O	1202	1208	Figure	Figure	NN	B-NP
O	1209	1210	2	2	CD	I-NP
O	1210	1211	(	(	(	O
O	1211	1212	b	b	NN	B-NP
O	1212	1213	)	)	)	O
O	1213	1214	)	)	)	O
O	1214	1215	.	.	.	O

O	1216	1219	The	The	DT	B-NP
O	1220	1224	most	most	RBS	I-NP
O	1225	1233	dramatic	dramatic	JJ	I-NP
O	1234	1240	effect	effect	NN	I-NP
O	1241	1243	on	on	IN	B-PP
O	1244	1251	glucose	glucose	NN	B-NP
O	1252	1261	tolerance	tolerance	NN	I-NP
O	1262	1271	following	follow	VBG	B-PP
O	1272	1276	CNTO	CNTO	NN	B-NP
O	1277	1280	530	530	CD	I-NP
O	1280	1281	-	-	HYPH	I-NP
O	1281	1290	treatment	treatment	NN	I-NP
O	1291	1294	was	be	VBD	B-VP
O	1295	1303	observed	observe	VBN	I-VP
O	1304	1306	on	on	IN	B-PP
O	1307	1310	day	day	NN	B-NP
O	1311	1313	14	14	CD	I-NP
O	1314	1319	where	where	WRB	B-ADVP
O	1320	1327	glucose	glucose	NN	B-NP
O	1328	1331	was	be	VBD	B-VP
O	1332	1339	cleared	clear	VBN	I-VP
O	1340	1344	from	from	IN	B-PP
O	1345	1356	circulation	circulation	NN	B-NP
O	1357	1359	by	by	IN	B-PP
O	1360	1363	the	the	DT	B-NP
O	1364	1366	15	15	CD	I-NP
O	1366	1367	-	-	HYPH	I-NP
O	1367	1373	minute	minute	NN	I-NP
O	1374	1378	time	time	NN	I-NP
O	1379	1384	point	point	NN	I-NP
O	1385	1386	(	(	(	O
O	1386	1392	Figure	Figure	NN	B-NP
O	1393	1394	2	2	CD	I-NP
O	1394	1395	(	(	(	O
O	1395	1396	a	a	DT	O
O	1396	1397	)	)	)	O
O	1397	1398	)	)	)	O
O	1398	1399	.	.	.	O

O	1400	1404	CNTO	CNTO	NN	B-NP
O	1405	1408	530	530	CD	I-NP
O	1408	1409	-	-	HYPH	O
O	1409	1417	mediated	mediate	VBN	B-NP
O	1418	1430	acceleration	acceleration	NN	I-NP
O	1431	1433	of	of	IN	B-PP
O	1434	1441	glucose	glucose	NN	B-NP
O	1442	1453	utilization	utilization	NN	I-NP
O	1454	1457	was	be	VBD	B-VP
O	1458	1468	diminished	diminish	VBN	I-VP
O	1469	1472	but	but	CC	O
O	1473	1478	still	still	RB	B-ADVP
O	1479	1490	significant	significant	JJ	B-ADJP
O	1491	1493	by	by	IN	B-PP
O	1494	1497	day	day	NN	B-NP
O	1498	1500	28	28	CD	I-NP
O	1501	1504	and	and	CC	O
O	1505	1508	not	not	RB	B-VP
O	1509	1513	seen	see	VBN	I-VP
O	1514	1516	by	by	IN	B-PP
O	1517	1520	day	day	NN	B-NP
O	1521	1523	35	35	CD	I-NP
O	1524	1525	(	(	(	O
O	1525	1531	Figure	Figure	NN	B-NP
O	1532	1533	2	2	CD	I-NP
O	1533	1534	(	(	(	O
O	1534	1535	b	b	NN	B-NP
O	1535	1536	)	)	)	O
O	1536	1537	)	)	)	O
O	1537	1538	.	.	.	O

O	1539	1549	Hemoglobin	Hemoglobin	NN	B-NP
O	1550	1556	levels	level	NNS	I-NP
O	1557	1565	followed	follow	VBD	B-VP
O	1566	1567	a	a	DT	B-NP
O	1568	1575	similar	similar	JJ	I-NP
O	1576	1580	time	time	NN	I-NP
O	1580	1581	-	-	HYPH	B-NP
O	1581	1590	dependent	dependent	JJ	I-NP
O	1591	1597	change	change	NN	I-NP
O	1597	1598	,	,	,	O
O	1599	1606	showing	show	VBG	B-VP
O	1607	1609	an	an	DT	B-NP
O	1610	1618	increase	increase	NN	I-NP
O	1619	1623	that	that	WDT	B-NP
O	1624	1630	peaked	peak	VBD	B-VP
O	1631	1633	on	on	IN	B-PP
O	1634	1637	day	day	NN	B-NP
O	1638	1640	22	22	CD	I-NP
O	1641	1644	and	and	CC	O
O	1645	1653	returned	return	VBD	B-VP
O	1654	1656	to	to	TO	B-PP
O	1657	1663	normal	normal	JJ	B-NP
O	1664	1670	levels	level	NNS	I-NP
O	1671	1673	by	by	IN	B-PP
O	1674	1677	day	day	NN	B-NP
O	1678	1680	29	29	CD	I-NP
O	1681	1682	(	(	(	O
O	1682	1688	Figure	Figure	NN	B-NP
O	1689	1690	2	2	CD	I-NP
O	1690	1691	(	(	(	O
O	1691	1692	c	c	NN	B-NP
O	1692	1693	)	)	)	O
O	1693	1694	)	)	)	O
O	1694	1695	.	.	.	O

O	1696	1703	Similar	Similar	JJ	B-NP
O	1704	1711	studies	study	NNS	I-NP
O	1712	1716	were	be	VBD	B-VP
O	1717	1726	completed	complete	VBN	I-VP
O	1727	1729	in	in	IN	B-PP
O	1730	1734	lean	lean	JJ	B-NP
O	1735	1745	littermate	littermate	JJ	I-NP
O	1746	1750	mice	mouse	NNS	I-NP
O	1751	1754	fed	feed	VBD	B-VP
O	1755	1756	a	a	DT	B-NP
O	1757	1763	normal	normal	JJ	I-NP
O	1764	1768	chow	chow	NN	I-NP
O	1769	1773	diet	diet	NN	I-NP
O	1773	1774	.	.	.	O

O	1775	1779	Mice	Mouse	NNS	B-NP
O	1780	1781	(	(	(	O
O	1781	1782	n	n	NN	B-NP
O	1783	1784	=	=	SYM	B-VP
O	1785	1786	7	7	CD	B-NP
O	1786	1787	)	)	)	O
O	1788	1792	were	be	VBD	B-VP
O	1793	1798	given	give	VBN	I-VP
O	1799	1800	a	a	DT	B-NP
O	1801	1807	single	single	JJ	I-NP
O	1808	1822	administration	administration	NN	I-NP
O	1823	1825	of	of	IN	B-PP
O	1826	1830	CNTO	CNTO	NN	B-NP
O	1831	1834	530	530	CD	I-NP
O	1835	1836	(	(	(	O
O	1836	1837	0	0	CD	B-NP
O	1837	1838	.	.	.	O
O	1838	1840	01	01	CD	B-NP
O	1840	1841	-	-	:	O
O	1841	1842	0	0	CD	B-NP
O	1842	1843	.	.	.	O
O	1843	1844	3	3	CD	B-NP
O	1845	1847	mg	mg	NN	I-NP
O	1847	1848	/	/	SYM	B-NP
O	1848	1850	kg	kg	NN	I-NP
O	1850	1851	)	)	)	O
O	1851	1852	,	,	,	O
O	1853	1856	and	and	CC	O
O	1857	1864	glucose	glucose	NN	B-NP
O	1865	1874	tolerance	tolerance	NN	I-NP
O	1875	1880	tests	test	NNS	I-NP
O	1881	1885	were	be	VBD	B-VP
O	1886	1895	completed	complete	VBN	I-VP
O	1896	1901	after	after	IN	B-PP
O	1902	1903	1	1	CD	B-NP
O	1904	1907	and	and	CC	I-NP
O	1908	1910	14	14	CD	I-NP
O	1911	1915	days	day	NNS	I-NP
O	1915	1916	.	.	.	O

O	1917	1919	As	As	IN	B-SBAR
O	1920	1922	we	we	PRP	B-NP
O	1923	1931	observed	observe	VBD	B-VP
O	1932	1934	in	in	IN	B-PP
O	1935	1938	the	the	DT	B-NP
O	1939	1947	diabetic	diabetic	JJ	I-NP
O	1948	1955	rodents	rodent	NNS	I-NP
O	1955	1956	,	,	,	O
O	1957	1959	no	no	DT	B-NP
O	1960	1971	significant	significant	JJ	I-NP
O	1972	1979	changes	change	NNS	I-NP
O	1980	1984	were	be	VBD	B-VP
O	1985	1989	seen	see	VBN	I-VP
O	1990	1992	in	in	IN	B-PP
O	1993	2000	glucose	glucose	NN	B-NP
O	2001	2010	clearance	clearance	NN	I-NP
O	2011	2013	24	24	CD	B-NP
O	2014	2019	hours	hour	NNS	I-NP
O	2020	2025	after	after	IN	B-PP
O	2026	2032	dosing	dosing	NN	B-NP
O	2032	2033	.	.	.	O

O	2034	2041	However	However	RB	B-ADVP
O	2041	2042	,	,	,	O
O	2043	2048	there	there	EX	B-NP
O	2049	2053	were	be	VBD	B-VP
O	2054	2065	significant	significant	JJ	B-NP
O	2066	2078	improvements	improvement	NNS	I-NP
O	2079	2081	in	in	IN	B-PP
O	2082	2085	the	the	DT	B-NP
O	2086	2090	area	area	NN	I-NP
O	2091	2096	under	under	IN	B-PP
O	2097	2100	the	the	DT	B-NP
O	2101	2106	curve	curve	NN	I-NP
O	2107	2109	in	in	IN	B-PP
O	2110	2113	the	the	DT	B-NP
O	2114	2121	glucose	glucose	NN	I-NP
O	2122	2131	tolerance	tolerance	NN	I-NP
O	2132	2136	test	test	NN	I-NP
O	2137	2139	in	in	IN	B-PP
O	2140	2147	animals	animal	NNS	B-NP
O	2148	2153	dosed	dose	VBN	B-VP
O	2154	2158	with	with	IN	B-PP
O	2159	2160	0	0	CD	B-NP
O	2160	2161	.	.	.	O
O	2161	2162	3	3	CD	B-NP
O	2163	2166	and	and	CC	I-NP
O	2167	2168	0	0	CD	I-NP
O	2168	2169	.	.	.	O
O	2169	2170	1	1	CD	B-NP
O	2171	2173	mg	mg	NN	I-NP
O	2173	2174	/	/	SYM	O
O	2174	2176	kg	kg	NN	B-NP
O	2177	2181	CNTO	CNTO	NN	I-NP
O	2182	2185	530	530	CD	I-NP
O	2186	2188	as	as	IN	B-SBAR
O	2189	2197	compared	compare	VBN	B-VP
O	2198	2200	to	to	TO	B-PP
O	2201	2204	PBS	PBS	NNS	B-NP
O	2205	2206	(	(	(	O
O	2206	2211	22865	22865	CD	B-NP
O	2211	2212	.	.	.	O
O	2212	2213	4	4	CD	B-NP
O	2214	2215	+	+	SYM	O
O	2215	2216	/	/	SYM	O
O	2216	2217	-	-	SYM	B-NP
O	2218	2222	1900	1900	CD	B-NP
O	2222	2223	.	.	SYM	I-NP
O	2223	2224	2	2	CD	I-NP
O	2224	2225	,	,	,	I-NP
O	2226	2231	24478	24478	CD	I-NP
O	2231	2232	.	.	.	I-NP
O	2232	2233	9	9	CD	I-NP
O	2234	2235	+	+	SYM	O
O	2235	2236	/	/	SYM	B-NP
O	2236	2237	-	-	SYM	B-NP
O	2238	2242	1093	1093	CD	B-NP
O	2242	2243	.	.	.	I-NP
O	2243	2244	4	4	CD	I-NP
O	2244	2245	,	,	,	O
O	2246	2249	and	and	CC	O
O	2250	2255	28773	28773	CD	B-NP
O	2255	2256	.	.	.	O
O	2256	2257	2	2	CD	B-NP
O	2258	2259	+	+	SYM	B-NP
O	2259	2260	/	/	SYM	I-NP
O	2260	2261	-	-	SYM	I-NP
O	2262	2266	1368	1368	CD	I-NP
O	2266	2267	.	.	SYM	I-NP
O	2267	2268	3	3	CD	I-NP
O	2268	2269	,	,	,	O
O	2270	2274	resp	resp	NN	B-NP
O	2274	2275	.	.	NN	I-NP
O	2275	2276	,	,	,	O
O	2277	2281	mean	mean	NN	B-NP
O	2282	2283	+	+	SYM	O
O	2283	2284	/	/	SYM	O
O	2284	2285	-	-	HYPH	O
O	2286	2289	SEM	SEM	NN	B-NP
O	2289	2290	)	)	)	O
O	2290	2291	.	.	.	O

O	2292	2297	There	There	EX	B-NP
O	2298	2302	were	be	VBD	B-VP
O	2303	2305	no	no	DT	B-NP
O	2306	2310	dose	dose	NN	I-NP
O	2310	2311	-	-	HYPH	B-NP
O	2311	2320	dependent	dependent	JJ	I-NP
O	2321	2328	changes	change	NNS	I-NP
O	2329	2331	in	in	IN	B-PP
O	2332	2335	the	the	DT	B-NP
O	2336	2343	fasting	fast	VBG	I-NP
B-Organism_substance	2344	2349	blood	blood	NN	I-NP
O	2350	2357	glucose	glucose	NN	I-NP
O	2357	2358	.	.	.	O

